MIT spinout Boltz launched as a public benefit corporation with a $28 million seed round to commercialize high‑accuracy AI models for biomolecular structure prediction and therapeutic design. Founders from MIT’s CSAIL/Barzilay lab positioned the platform to democratize drug discovery tools for academic and industry scientists. Venture capital activity echoed that momentum: Andreessen Horowitz (a16z) raised $700 million for its Bio + Health strategy, signaling sustained VC commitment to AI‑native biotech platforms and developer tools that accelerate early discovery and preclinical design.